Drug Interaction Report

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of maribavir, which is primarily metabolized by the isoenzyme. When maribavir (400 mg twice daily) was administered with the potent CYP450 3A4 inducer, rifampin (600 mg once daily), maribavir peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 39% and 60%, respectively. The interaction has not been studied with other, less potent inducers.

MANAGEMENT: The potential for diminished pharmacologic effects of maribavir should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.

Omaveloxolone should be taken on an empty stomach, at least one hour before eating. Do not consume grapefruit, grapefruit juice, or any supplements that contain grapefruit extract during treatment with omaveloxolone unless directed otherwise by your doctor. Grapefruit juice may increase the blood levels of omaveloxolone. This may increase the risk of side effects such as changes in the amount of cholesterol in the blood and changes in liver and heart function tests. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.